Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022;17:362–87.

Article  PubMed  Google Scholar 

Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611–25.

Article  CAS  PubMed  Google Scholar 

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–65.

Article  PubMed  Google Scholar 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19:254–66.

Article  CAS  PubMed  Google Scholar 

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–37.

Article  CAS  PubMed  Google Scholar 

Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol. 2022;40:546–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021;375: n2363.

Article  PubMed  Google Scholar 

Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128.

Article  PubMed  Google Scholar 

Yao S, Peng L, Elakad O, Kuffer S, Hinterthaner M, Danner BC, et al. One carbon metabolism in human lung cancer. Transl Lung Cancer Res. 2021;10:2523–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li G, Wu J, Li L, Jiang P. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage. Proc Natl Acad Sci U S A. 2021. https://doi.org/10.1073/pnas.2019822118.

Article  PubMed  PubMed Central  Google Scholar 

Gustafsson Sheppard N, Jarl L, Mahadessian D, Strittmatter L, Schmidt A, Madhusudan N, et al. The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferation. Sci Rep. 2015;5:15029.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Z, Leung GKK. More than a metabolic enzyme: MTHFD2 as a novel target for anticancer therapy? Front Oncol. 2020;10:658.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, Huang Y, Jiang C, Ou H, Guo B, Liao H, et al. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma. Dig Liver Dis. 2016;48:953–60.

Article  CAS  PubMed  Google Scholar 

Liu F, Liu Y, He C, Tao L, He X, Song H, et al. Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumour Biol. 2014;35:8685–90.

Article  CAS  PubMed  Google Scholar 

Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Lan Li L, et al. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest. 2017;127:1856–72.

Article  PubMed  PubMed Central  Google Scholar 

Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, et al. Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications. J Natl Cancer Inst. 2018. https://doi.org/10.1093/jnci/djy160.

Article  PubMed Central  Google Scholar 

Yu C, Yang L, Cai M, Zhou F, Xiao S, Li Y, et al. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes. J Cell Mol Med. 2020;24:1568–77.

Article  CAS  PubMed  Google Scholar 

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.

Article  CAS  PubMed  Google Scholar 

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.

Article  CAS  PubMed  Google Scholar 

Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, et al. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer. 2010;69:323–9.

Article  PubMed  Google Scholar 

Schaer DA, Geeganage S, Amaladas N, Lu ZH, Rasmussen ER, Sonyi A, et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy. Clin Cancer Res. 2019;25:7175–88.

Article  CAS  PubMed  Google Scholar 

Li K, Wu JL, Qin B, Fan Z, Tang Q, Lu W, et al. ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer. Cell Res. 2020;30:163–78.

Article  CAS  PubMed  Google Scholar 

Bohnenberger H, Kaderali L, Strobel P, Yepes D, Plessmann U, Dharia NV, et al. Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis. EMBO Mol Med. 2018. https://doi.org/10.15252/emmm.201708428.

Article  PubMed  PubMed Central  Google Scholar 

Buentzel J, Yao S, Elakad O, Lois AM, Brunies J, Konig J, et al. Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer. Medicine (Baltimore). 2019;98: e16712.

Article  CAS  PubMed  Google Scholar 

Bremer SCB, Conradi LC, Mechie NC, Amanzada A, Mavropoulou E, Kitz J, et al. Enhancer of zeste homolog 2 in colorectal cancer development and progression. Digestion. 2019. https://doi.org/10.1159/000504093.

Article  PubMed  Google Scholar 

Cordesmeyer R, Laskawi R, Schliephake H, Kauffmann P, Beck J, Bornemann-Kolatzki K, et al. Shallow whole genome sequencing of adenoid cystic carcinomas of the salivary glands identifies specific chromosomal aberrations related to tumor progression. Oral Oncol. 2020;103: 104615.

Article  CAS  PubMed  Google Scholar 

Elakad O, Haupl B, Labitzky V, Yao S, Kuffer S, von Hammerstein-Equord A, et al. Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. NPJ Precis Oncol. 2022;6:52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elakad O, Lois AM, Schmitz K, Yao S, Hugo S, Lukat L, et al. Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer. Cancer Med. 2020;9:3574–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Elakad O, Yao S, von Hammerstein-Equord A, Hinterthaner M, Danner BC, et al. Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS-mutated human pulmonary adenocarcinoma. Metabolites. 2022. https://doi.org/10.3390/metabo12070652.

Article  PubMed  PubMed Central